The search found 4125 results.
http://health-care-it.advanceweb.com/Editorial/Content/editorial.aspx?CTIID=2849
Lexington, MA – September 16, 2016 -- Imprivata® (NYSE: IMPR) (the “Company”), the healthcare IT security company, today announced the completion of its acquisition by leading private equity investment firm Thoma Bravo, LLC. Under the terms of the merger agreement, Imprivata shareholders are entitled to receive $19.25 in cash for each share of Imprivata common stock they hold.
This Nucleus Research guidebook provides third-party validation of Imprivata Confirm ID for ECPS’s ability to streamline and accelerate the prescription workflows, drive greater provider productivity, improve patient care, and reduce costs. The paper discusses key problems facing the healthcare industry, top considerations for an EPCS solution, and key benefits offered from Imprivata Confirm ID.
The DEA requires all practitioners who will be prescribing controlled substances electronically to undergo identity proofing, even if they have already been authorized to prescribe controlled substances using paper. This whitepaper outlines both individual and institutional identity proofing as well as the logical access control requirements necessary for a successful EPCS initiative.
http://health-care-it.advanceweb.com/Editorial/Search/AViewer.aspx?AN=HX_08aug1_hxp47.html&AD=08-01-2008